日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Real-World Comparison of Lenvatinib and Sorafenib as First-Line Treatments for Hepatocellular Carcinoma: A Multicenter Study

真实世界中乐伐替尼与索拉非尼作为肝细胞癌一线治疗方案的比较:一项多中心研究

Kang, Mira; Cha, Won Chul; Sinn, Dong Hyun; Jeong, Woo Kyoung; Kim, Do Young; Lee, Min Ji; Lim, Subin; Kim, DongKyu; Kim, Kyu-Pyo; Ryoo, Baek-Yeol; Choi, Won-Mook; Kim, Kang Mo; Kim, Ki-Hun; Lee, Doik; Choi, Eui Jun; Jung, Choungwon; Kim, Joohyun; Hong, Jung Yong

Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study

白蛋白-胆红素评分和治疗结果在肝细胞癌中的预后价值:一项大规模、多中心真实世界数据库研究

Kim, Kyu-Pyo; Kim, Kang Mo; Ryoo, Baek-Yeol; Choi, Won-Mook; Cha, Won Chul; Kang, Mira; Sinn, Dong Hyun; Goh, Myung Ji; Kim, Do Young; Lee, Min Ji; Lim, Subin; Kim, DongKyu; Baek, Kyoungdae; Kim, Joohyun; Choi, Eui Jun; Lee, Doik; Kim, Jung-Ae; Kim, Ki-Hun

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD

比较慢性阻塞性肺疾病患者使用长效毒蕈碱受体拮抗剂与吸入性糖皮质激素联合长效β2受体激动剂治疗肺炎的发生率

Lee, Eung Gu; Kim, Youlim; Hwang, Yong Il; Yoo, Kwang Ha; Lee, So Eun; Jung, Kyung Yoon; Lee, Doik; Park, Yong Bum; Rhee, Chin Kook

Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA versus ICS/LABA in COPD Management: Findings from Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study

在慢性阻塞性肺疾病(COPD)管理中,从启动长效抗胆碱能药物(LAMA)与吸入性糖皮质激素/长效β2受体激动剂(ICS/LABA)治疗到启动三联疗法的升级时间:韩国真实世界噻托溴铵与ICS/LABA使用率比较研究(CITRUS研究)的结果

Lee, Ye Jin; Rhee, Chin Kook; Hwang, Yong Il; Yoo, Kwang Ha; Lee, So Eun; Lee, Doik; Park, Yong Bum; Kim, Youlim

Patient Posture Monitoring System Based on Flexible Sensors

基于柔性传感器的患者姿势监测系统

Cha, Youngsu; Nam, Kihyuk; Kim, Doik